Metabolic syndrome and chronic kidney disease: A Japanese perspective on a worldwide problem

Journal of Nephrology

Volumn 21, Issue 3, 2008, Pages 305-312

  Iseki, Kunitoshi ^a  

^a UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

Author keywords

Chronic kidney disease; End stage renal disease; Glomerular filtration rate; Proteinuria; Screening

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ATHEROSCLEROSIS; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DEVELOPING COUNTRY; DYSLIPIDEMIA; ETHNIC GROUP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; JAPANESE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; OBESITY; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PROTEINURIA; RENAL REPLACEMENT THERAPY; REVIEW; SLEEP APNEA SYNDROME; WEIGHT REDUCTION; ANIMAL; CHRONIC DISEASE; JAPAN; KIDNEY DISEASE; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; CHRONIC DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; JAPAN; KIDNEY DISEASES; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 52049116155     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2008;108:2154-2169.
2. Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005;16:3728-3735.
3. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
4. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-1295.
5. Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68:228-236.
6. Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264-1271.
7. Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844-850.
8. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a Southeast Asian population: a 12-year cohort study. J Am Soc Nephrol. 2005;16:791-799.
9. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal followup and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659-663.
10. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66:753-760.
11. Wakai K, Nakai S, Kikuchi K, et al. Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. Nephrol Dial Transplant. 2004;16:2044-2052.
12. Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005;365:1398-1405.
13. Tanaka H, Shiohira Y, Uezu Y, et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006;69:369-374.
14. Kadowaki T, Sekikawa A, Murata K, et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int J Obes. 2006;30:1163-1165.
15. Mandavilli A, Cyranovski D. Asia's big problem. Nat Med. 2004;10:325-327.
16. Alberti KG, Zimmet PZ; for the WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-2497.
18. Committee for the definition of metabolic syndrome. Definition of metabolic syndrome and diagnostic criteria [in Japanese]. Jpn J Med. 2005;94:794-809.
19. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498-1509.
20. Matsuzawa Y. Pathophysiology and molecular mechanism of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev. 1997;13:3-13.
21. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996;2:800-802.
22. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S170-S212.
23. Ma Y, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937-2944.
24. Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11:41-50.
25. Imai E, Horio M, Nitta K, et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis. 2007;50:927-937.
26. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Study. Am J Kidney Dis. 2003;41:1-12.
27. Imai E, Horio M, Iseki K, et al. Prevalence of chronic kidney disease (CKD) in Japanese general population predicted by MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007;11:156-163.
28. Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. J Am Soc Nephrol. 2006;69:2155-2161.
29. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304:930-933.
30. Rahmouni K, Correia MLG, Haynes WG, et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45:9-14.
31. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol. 2004;15:2775-2791.
32. Chen J, Muntner P, Hamm L, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167-174.
33. Metcalf P, Baker J, Scott A, et al. Albuminuria in people at least 40 years old: effect of obesity, hypertension, and hyperlipidemia. Clin Chem. 1992;38:1802-1808.
34. Ramirez SP, McClellan W, Port FK, Hsu SI. Risk factors for proteinuria in a large, multiracial, southeast Asian population. J Am Soc Nephrol. 2002;13:1907-1917.
35. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. Kidney Int. 2002;62:956-962.
36. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol, levels predicts development of proteinuria. Kidney Int. 2002;62:1743-1749.
37. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134-2140.
38. Ninomiya T, Kiyohara Y, Kubo M, et al. Metabolic syndrome and CKD in a general Japanese population: The Hisayama study. Am J Kidney Dis. 2006;48:383-391.
39. Tozawa M, Iseki C, Tokashiki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res. 2007;30:937-943.
40. Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol. 2006;17:1453-1459.
41. Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870-1876.
42. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21-28.
43. Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O. Obesity and risk of chronic renal failure. J Am Soc Nephrol. 2006;17:1695-1702.
44. Locatelli F, Pozzoni P, del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol. 2006;17:S81-S85.
45. Praga M, Hernandez E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001;16:1790-1798.
46. Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis. 2001;37:720-727.
47. Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70-74.
48. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908-1919.
49. Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293-301.
50. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis. 2002;39:1-11.
51. Nishida M, Miyazawa JI, Tokunaga K, et al. Early morphologic changes of atherosclerosis induced by ventromedial hypothalamic lesion in the spontaneously diabetic Goto- Kakizaki rat. J Lab Clin Med. 1997;129:200-207.
52. Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med. 1974;81:440-447.
53. Praga M, Hernandez E, Herrero JC, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 2000;58:2111-2118.
54. Ahmed SB, Fisher ND, Stevanovic R, et al. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension. 2005;46:1316-1320.
55. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med. 2003;348:101-108.
56. Sayer AA, Syddall HE, Dennison EM, et al. Birth weight, weight at 1 y of age, and body composition in older men: findings from the Hertfordshire Cohort Study. Am J Clin Nutr. 2004;80:199-203.
57. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure: less of one, more the other? Am J Hypertens. 1988;1:335-347.
58. Giacchetti G, Faloia E, Mariniello B, et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens. 2002;15:381-388.
59. Serazin-Leroy V, Morot M, de Mazancourt P, Giudicelli Y. Androgen regulation and site specificity of angiotensinogen gene expression and secretion in rat adipocytes. Am J Physiol. 2000;279:E1398-E1405.
60. Zhang SL, Chen X, Hsieh TJ, et al. Hyperglycemia induces insulin resistance on angiotensinogen gene expression in diabetic rat kidney proximal tubular cells. J Endocrinol. 2002;172:333-344.
61. Anderson PW, Zhang XY, Tian J, et al. Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells. Kidney Int. 1996;50:745-753.
62. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Resp Crit Care Med. 2002;165:1217-1239.
63. Duran J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Resp Crit Care Med. 2001;163:685-689.
64. He J, Kryger MH, Zorick FJ, Conway W, Roth T. Mortality and apnea index in obstructive sleep apnea: experience in 385 male patients. Chest. 1988;94:9-14.
65. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Resp Crit Care Med. 2001;163:19-25.
66. Stepanski E, Faber M, Zorick F, Basner R, Roth T. Sleep disorders in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:192-197.
67. Hui DS, Wong TY, Ko FW, et al. Prevalence of sleep disturbances in Chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 2000;36:783-788.
68. Iseki K, Tohyama K, Matsumoto T, Nakamura H. High Prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD). Hypertens Res. 2008;31:249-255.
69. Orth SR. Smoking and the kidney. J Am Soc Nephrol. 2002;13:1663-1672.
70. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290:F625-F631.
71. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuria patients. Am J Kidney Dis. 2003;41:319-327.
72. Praga M, Morales E. Weight loss and proteinuria. Contrib Nephrol. 2006;151:221-229.
73. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793-808.
74. Navarro-Diaz M, Serra A, Romero R, et al. Effect of drastic loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol. 2006;17:S213-S217.
75. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260-269.
76. Marin JM, Carrizo SJ, Vincente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365:1046-1053.
77. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med. 2003;348:1233-1241.
78. Yingzhong Y, Droma Y, Rili G, Kubo K. Regulations of body weight by leptin, with special reference to hypoxia-induced regulation. Intern Med. 2006;41:941-946.
79. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247-259.
80. Japanese Society of Nephrology. CKD Practice Guide. Tokyo: Igakusha; 2007:1-116.
81. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002;13(Suppl 1):S37-S40.
82. Boulware LE, Jaar BG, Tarver Carr MG, et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101-3114
83. Yamagata K, Iseki K, Nitta K, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12:1-8.
84. Uhlig K, MacLeod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology: a position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kidney Int. 2006;70:2058-2065.